Headed for a blockbuster smash, Roche picks up another key OK for landmark MS drug Ocrevus
Roche’s quest to make its pioneering MS drug Ocrevus into a multibillion-dollar blockbuster has gathered some added steam with an EU marketing approval — 9 months after the big FDA green light came through.
Analysts expect that Ocrevus can rack up $3 billion in peak sales, with the pharma giant rolling up not that far from $1 billion in just the first 9 months in the US. That’s exactly the kind of blockbuster smash that Roche needs now as franchise drugs like Rituxan, Herceptin and Avastin are shredded by generic rivals.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
